Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.71 |
| ▸ | TP53 | P04637 | 1/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.65 |
| ▸ | NPC1 | O15118 | 8/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | HPGD | P15428 | 3/20 | 0.65 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 9/20 | 0.64 |
| ▸ | POLB | P06746 | 4/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | GFER | P55789 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1494680 | 0.86 | NPC1 (0.72) | MAPTCYP1A2KDM4ENPC1SMN1; SMN2 | |
| SCHEMBL1495002 | 0.86 | CYP1A2 (0.72) | MAPTTP53CYP1A2KDM4ENPC1 | |
| SCHEMBL12765291 | 0.85 | KDM4E (0.64) | MAPTTP53CYP1A2KDM4ENPC1 | |
| SCHEMBL13381558 | 0.84 | CYP1A2 (0.63) | MAPTTP53CYP1A2KDM4ENPC1 | |
| SCHEMBL4727131 | 0.83 | KDM4E (0.64) | MAPTTP53CYP1A2KDM4ENPC1 | |
| SCHEMBL19322176 | 0.83 | KDM4E (0.82) | MAPTCYP1A2KDM4ENPC1SMN1; SMN2 | |
| SCHEMBL1494891 | 0.82 | TP53 (0.66) | MAPTTP53KDM4ENPC1SMN1; SMN2 | |
| SCHEMBL31683150 | 0.82 | MAPT (0.57) | MAPTTP53CYP1A2KDM4ENPC1 | |
| SCHEMBL26604754 | 0.82 | MAPT (0.57) | MAPTTP53CYP1A2KDM4ENPC1 | |
| SCHEMBL1495055 | 0.81 | TP53 (0.57) | MAPTTP53KDM4ENPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053915-A1 | HETEROCYCLIC INHIBITORS OF AN Hh-SIGNAL CASCADE, MEDICINAL COMPOSITIONS BASED THEREON AND METHODS FOR TREATING DISEASES CAUSED BY THE ABERRANT ACTIVITY OF AN Hh-SIGNAL SYSTEM | ALLA CHEM, LLC (US) | 2011-03-03 | — | — | US | claimed |
| US-8486945-B2 | Heterocyclic inhibitors of an Hh-signal cascade, medicinal compositions based thereon and methods for treating diseases caused by the aberrant activity of an Hh-signal system | Ivachtchenko, Alexandre Vasilievich (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486945-B2 | Heterocyclic inhibitors of an Hh-signal cascade, medicinal compositions based thereon and methods for treating diseases caused by the aberrant activity of an Hh-signal system | Ivachtchenko, Alexandre Vasilievich (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486945-B2 | Heterocyclic inhibitors of an Hh-signal cascade, medicinal compositions based thereon and methods for treating diseases caused by the aberrant activity of an Hh-signal system | Ivachtchenko, Alexandre Vasilievich (US) | 2013-07-16 | — | — | US | disclosed |
| US-20110053915-A1 | HETEROCYCLIC INHIBITORS OF AN Hh-SIGNAL CASCADE, MEDICINAL COMPOSITIONS BASED THEREON AND METHODS FOR TREATING DISEASES CAUSED BY THE ABERRANT ACTIVITY OF AN Hh-SIGNAL SYSTEM | ALLA CHEM, LLC (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053915-A1 | HETEROCYCLIC INHIBITORS OF AN Hh-SIGNAL CASCADE, MEDICINAL COMPOSITIONS BASED THEREON AND METHODS FOR TREATING DISEASES CAUSED BY THE ABERRANT ACTIVITY OF AN Hh-SIGNAL SYSTEM | ALLA CHEM, LLC (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053915-A1 | HETEROCYCLIC INHIBITORS OF AN Hh-SIGNAL CASCADE, MEDICINAL COMPOSITIONS BASED THEREON AND METHODS FOR TREATING DISEASES CAUSED BY THE ABERRANT ACTIVITY OF AN Hh-SIGNAL SYSTEM | ALLA CHEM, LLC (US) | 2011-03-03 | — | — | US | disclosed |
| WO-2008029152-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053915-A1 | HETEROCYCLIC INHIBITORS OF AN Hh-SIGNAL CASCADE, MEDICINAL COMPOSITIONS BASED THEREON AND METHODS FOR TREATING DISEASES CAUSED BY THE ABERRANT ACTIVITY OF AN Hh-SIGNAL SYSTEM | SHH, SMO, GLI1 | MAPT 3985/4885TP53 1151/4885CYP1A2 3501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.